Summary
U.S. Patent 6,028,071 covers a class of compounds used for therapeutic purposes, notably in the treatment of autoimmune diseases and inflammatory conditions. The patent’s claims are broad, covering both the compounds and their methods of use. The patent landscape includes related patents assigned primarily to the original assignee, with numerous filings around similar chemical classes and indications. The patent's scope spans composition claims, method claims, and formulations, making it significant in the landscape of drugs aimed at modulating immune responses.
Scope and Claims Analysis
1. Patent Overview
U.S. Patent 6,028,071 was issued on February 22, 2000, to Berlex Laboratories Inc. The patent's primary focus is on a specific chemical class of immunomodulatory agents based on a heterocyclic structure. The patent claims include:
- Compounds characterized by a core heterocyclic structure with various substitutions.
- Pharmaceutical compositions comprising these compounds.
- Methods of treating autoimmune and inflammatory diseases using these compounds.
2. Chemical Scope
The patent broadly claims "heterocyclic compounds" with various substituents, defining a genus that encompasses potentially hundreds of specific compounds. The chemical scope includes derivatives of a core structure with particular functional groups, focusing on modifications that influence immunomodulatory activity.
3. Claim Types and Coverage
-
Compound Claims: Cover individual chemical entities with specific substitution patterns, providing a foundation for structure-based patent protection.
-
Composition Claims: Protect pharmaceutical formulations containing the claimed compounds, including carriers and excipients.
-
Method Claims: Include methods of administering the compounds for treating autoimmune conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
4. Claim Breadth and Limitations
Claim breadth extends to:
- Variations in substituents that do not substantially alter the core heterocyclic structure.
- Methods involving specific dosages, administration routes, or treatment regimens.
Limitations include the emphasis on the heterocyclic core and certain specified substituents. The claims do not extend to unrelated chemical classes or unrelated therapeutic indications.
Patent Landscape
1. Subsequent Patent Filings
Multiple foreign and U.S. patents cite or are related to the 6,028,071 patent, notably:
- WO patents (e.g., WO 1999/046849) that expand on the chemical class and use.
- U.S. continuation and divisional patents covering narrower species or specific therapeutic methods.
- Patent filings by competitors seeking to develop similar compounds or methods of use.
2. Related Patents and Patent Family
The patent family encompasses roughly 20 patent families worldwide, with notable filings in Europe, Japan, and Canada. Many of these filings seek to:
- Protect specific derivatives within the scope.
- Cover particular therapeutic indications.
- Claim improvements or formulations that enhance bioavailability or reduce toxicity.
3. Patent Validity and Challenges
The patent's validity was examined during prosecution, with prior art references cited that questioned the novelty of specific compounds. To date, the patent has remained unenforced through litigation but remains a key asset for the patent holder.
4. Patent Expiry and Legal Status
The patent was set to expire in February 2017, but potential extensions or supplementary protection certificates (SPCs) could have extended patent rights, depending on jurisdiction.
Implications for Development and Commercialization
The broad chemical and method claims create a substantial patent barrier for competitors developing similar immunomodulators. Freedom-to-operate analyses must account for the specific compounds covered and any narrow claims in related patents. The patent landscape indicates active prosecution and defensive filings, signaling ongoing interest in the chemical class for autoimmune indications.
Key Takeaways
- U.S. Patent 6,028,071 claims a broad class of heterocyclic compounds for immunomodulation.
- The scope includes compound, composition, and method claims with significant breadth within the specified chemical core.
- The patent family spans multiple jurisdictions, with ongoing patent filings targeting specific derivatives and uses.
- The patent expired in 2017, but exclusivity may be maintained via related patents or regulatory exclusivities.
- Ongoing patent filings and litigation should be monitored to assess potential infringement or new patent protections.
FAQs
Q1: What is the primary chemical structure protected under U.S. Patent 6,028,071?
It covers heterocyclic compounds with specific substitution patterns on a core heterocyclic scaffold, designed for immunomodulatory activity.
Q2: Does the patent cover formulations or just the chemical compounds?
It covers both chemical compounds and pharmaceutical compositions containing those compounds.
Q3: Are method of use claims included in the patent?
Yes, the patent claims include methods of treating autoimmune and inflammatory diseases using the compounds.
Q4: Can similar compounds be developed around this patent's scope?
Developers can modify substituents or the core structure to avoid infringement, but extensive due diligence is necessary to ensure non-infringement.
Q5: Has the patent been challenged or litigated?
No significant enforcement litigation is publicly documented; however, the patent was examined during prosecution, with prior art considered to challenge novelty.
References
- U.S. Patent 6,028,071.
- Patent Family Databases, WIPO and EPO.
- Related patent filings and assignments, available via public patent databases.
